Company ProfilePremium

Cofinimmo SA

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Cofinimmo SA - Company showcase

Year Founded & Workforce

1983

127 Employees

Cofinimmo SA logo

Cofinimmo SA Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Cofinimmo SA Overview

FieldDetail
Entity profiledAedifica SA/NV (absorbing company of Cofinimmo SA/NV)
Legal formPublic limited liability company; public regulated real estate company (RREC / SIR / GVV) under Belgian law
Registered office / HQRue Belliard 40 (box 11), 1040 Brussels, Belgium
Enterprise number0877.248.501 (RLE Brussels)
Incorporation7 November 2005, Belgium
ListingsEuronext Brussels (since 2006 IPO) and Euronext Amsterdam (since November 2019)
TickerAED (Euronext Brussels/Amsterdam); AOO (German venues)
ISINBE0003851681
Index membershipBEL 20 (since March 2020, weighting ~4.7% at 30.06.2026), BEL ESG, EPRA Europe (~2.9% weighting), EPRA Belgium (~34.6%), GPR 250, Stoxx Europe 600
Fiscal year end31 December
Shares outstanding92,632,604 (after 1 July 2026 merger issuance)
Share price (approx.)~EUR 62.30 (Lang & Schwarz weekend quote, 18 Oct 2026; secondary source)
Market capitalisation (derived)~EUR 5.77 bn (92.63m shares × EUR 62.30). Note: one secondary source quoted EUR 5.2 bn on 16 Oct 2026; the discrepancy likely reflects a stale share count. Company-reported market cap was EUR 5.89 bn at 30.06.2026 on 83.47m shares at EUR 70.60
52-week rangeEUR 60.35 – 80.05 (secondary source, 16 Oct 2026)
EmployeesAedifica standalone: ~127–131 (aggregator data, pre-merger). Combined headcount after absorbing Cofinimmo's team: not publicly disclosed
Statutory auditorAedifica: not confirmed in this research (H1 2026 report contains a limited-review auditor's report; name not captured). Legacy Cofinimmo: KPMG Réviseurs d'Entreprises, represented by Jean-François Kupper (Cofinimmo FY2025 press release, 20.02.2026)
Websitewww.aedifica.eu (legacy: www.cofinimmo.com)
Credit ratingsS&P: BBB+ / stable / A-2 (upgraded March 2026, reconfirmed 20 July 2026). Moody's: A3 / stable, first-time issuer rating (reported 15 Oct 2026 by secondary sources; see Section 21)

Legacy entity (for reference)

FieldDetail
Legal nameCofinimmo SA/NV
Enterprise number0426.184.049 (Brussels Register of Legal Entities)
Founded1,983
HQAvenue de Tervueren / Tervurenlaan 270, Brussels ("The Gradient" building)
Former listingEuronext Brussels, ticker COFB, ISIN BE0003593044; BEL 20 constituent
REIT regimesBelgian RREC, French SIIC, Dutch FBI, Spanish SOCIMI (per company and press descriptions)
Shares38,096,217 issued at 31.12.2025
Market cap at 31.12.2025EUR 3,017 m (share price EUR 79.20)
Last CEO / CFOJean-Pierre Hanin (CEO) / Jean Kotarakos (CFO)
StatusDelisted 1 July 2026; absorbed by Aedifica
MetricFY2023FY2024FY2025
Aedifica employees (headcount)—131127

Note: 2024–2025 headcounts come from data aggregators (roic.ai, Investing.com) and are not company-verified; Cofinimmo headcount was not captured in this research.

Aedifica, following its absorption of Cofinimmo, is Europe's largest listed healthcare real estate investment trust by portfolio value. At 30 June 2026 it owned a EUR 12.5 bn portfolio of 1,723 properties, including a EUR 11.1 bn healthcare book of 924 care properties housing roughly 67,400 residents and 12,900 children across nine countries: Belgium, Germany, Finland, the UK, the Netherlands, France, Ireland, Spain and Italy. Its business model is long-lease, largely triple- or double-net rental to professional care operators, indexed to inflation, with a 15-year WAULT and 99.1% occupancy. The group carries two non-core legacy segments from Cofinimmo: Brussels offices (EUR 874 m) and the Pubstone pub portfolio leased to AB InBev (EUR 468 m). With BBB+ (S&P) and A3 (Moody's) ratings, a 1.9% average cost of debt and EUR 16 m targeted run-rate synergies, the group is positioned as the scale consolidator in a fragmented, demographically driven European care property market.


What the company does

Aedifica is a specialised property investor and developer. It acquires, develops (mostly through pre-let development partnerships), owns and manages real estate used for care. It leases these assets on long-term contracts to private, non-profit and public operators. It does not provide care services itself; operating risk sits with tenants, while Aedifica bears property, re-letting, tenant-credit and valuation risk.

After absorbing Cofinimmo, the group has three reportable activity lines:

  1. Healthcare real estate (89% of total portfolio fair value; ~88% of contractual rents at 30.06.2026). Sub-types by fair value of the total portfolio: elderly care homes 60%, mixed-use elderly care 13%, cure centres (acute, rehabilitation and psychiatric clinics) 7%, childcare centres 3%, senior housing 2%, disabled-care facilities 2%, other care 2%.

  2. Offices (7% of fair value; EUR 874 m; 23 sites, all in Belgium, largely Brussels CBD), inherited from Cofinimmo.

  3. Distribution networks (4% of fair value; EUR 468 m; 776 sites), mainly the Pubstone portfolio of pubs and restaurants in Belgium (577 sites) and the Netherlands (185 sites) leased to AB InBev.

Source: Aedifica 2026 Half Year Financial Report (01.09.2026).

Business and revenue model

Revenue dimensionCharacterisation
Revenue type~100% rental income (lease/"subscription-like" contractual rent); minor finance-lease interest income, development interest and writeback of sold lease receivables
Product vs service vs licensingNo product, service or licensing revenue in the conventional sense; revenue is real-estate rent
Contract structureLong leases. Triple-net (operator bears operating costs, maintenance and vacancy) typical in Belgium, UK, Ireland and Spain, and often the Netherlands and Italy. Double-net (owner keeps roof, structure and facade) typical in Germany, Finland and France
IndexationAnnual CPI-linked indexation, usually on the contract anniversary date. H1 2026 like-for-like rental growth of 1.7% was made up of +1.9% indexation, +0.2% reversion and contingent rents, and −0.4% FX
Lease durationWAULT 15 years for total portfolio, 16 years for healthcare (30.06.2026)
Occupancy99.1% total; 99.7% healthcare (EPRA methodology, 30.06.2026)
Gross yield6.1% on fair value (healthcare 6.0%, offices 6.3%, distribution 7.4%)

Value-chain position

Aedifica sits between capital markets (equity, bonds, bank debt, commercial paper) and care operators. It provides long-dated real-estate capital that lets operators run asset-light models. It increasingly acts as a developer-owner: the committed investment programme was EUR 531 m at 30.06.2026, of which EUR 268 m already spent. These are mostly pre-let new builds in Finland, Spain, Ireland, Germany and the UK, with a targeted initial yield on cost of 6–6.5% (actual pipeline average 5.8% after inheriting legacy Cofinimmo Spanish projects).

Customers and end-markets

Customers: About 190 tenant groups (Aedifica H1 2026). Largest exposures by contractual rent: Clariane 12%, Colisée (incl. Armonea) 7%, AB InBev 4%, Emeis 4%, DomusVi 3%, Emera 3%, Azurit Rohr 3%, Vulpia 3%, Maria Mallaband 2%, Finnish municipalities/wellbeing services counties 2%. Others account for 57%.

End-markets: European elderly care (dominant), childcare (Finland), disabled care, acute and rehabilitation care (France, Belgium), mental health, plus Brussels office space and Benelux hospitality (pubs).

Ultimate demand driver: the over-80 population in the EU and UK, which the company puts above 31 million in 2025 and expects to double to over 60 million by 2060.

Company's own description (paraphrased)

In its latest reporting, Aedifica describes itself as a Belgian REIT focused on European healthcare property, especially elderly-care housing. It frames the Cofinimmo merger as creating Europe's leading healthcare REIT, with lower capital costs and sustainable EPS growth as the main value-creation levers (Aedifica H1 2026 report). Cofinimmo's last self-description (FY2025 release) presented it as a 40-year-old owner of care, living and working spaces under the tagline "Caring, Living and Working – Together in Real Estate", with healthcare in nine countries as its core.

Independent characterisation

Analytically, the combined group is a pure-play European healthcare landlord with a non-core diversified tail of about 11% of portfolio value (offices plus pubs). This tail is a legacy of Cofinimmo's history as Belgium's largest diversified REIT. The investment case rests on three things:

  1. Inflation-indexed, very long contractual cash flows.

  2. A funding-cost advantage from investment-grade ratings and scale.

  3. Disciplined capital recycling out of non-core assets.

Its key sensitivities are operator health, especially Clariane and Colisée/Armonea, together about 19% of rent; refinancing costs as legacy cheap hedges roll off; and the trading discount to NAV, which governs whether equity-funded growth is accretive.

Strategy

Stated strategy (themes from latest reporting)

  1. Create and lead Europe's healthcare REIT platform: use scale to lower capital costs and grow EPRA EPS sustainably. Management describes the combined platform as built for the next phase of growth in healthcare real estate (H1 2026 report).

  2. Healthcare focus with non-core recycling: Aedifica remains focused on healthcare real estate, while continuing asset rotation (EUR 110 m in disposals budgeted for 2026, EUR 54 m achieved by 1 September).

  3. Pre-let development as growth engine: pipeline target of EUR 500–750 m, fully pre-let, at a 6–6.5% yield on cost.

  4. Balance-sheet discipline: debt-to-assets in the low-40s, no intention to lever above 42–43%, 45% internal ceiling.

  5. Sustainability integration: 61% of committed long-term debt linked to sustainability KPIs; net energy use intensity target of 130 kWh/m² by 2030.

  6. Dividend growth: payout based on consolidated EPRA Earnings; 2026 DPS guided at EUR 4.20 (+5%).

Strategic initiatives (last 24 months)

InitiativeDateDescription / targetsStatus
Combination with CofinimmoMay 2025 – Jul 2026All-share exchange offer at 1.185 plus merger at 1.1784; ≥EUR 16 m run-rate synergiesCompleted; integration ongoing
Synergy programme2026–2027~EUR 5.5 m in 2026 (one-third of run rate); full ≥EUR 16 m run-rate during 2027On track per H1 2026 call
BCA divestment remedyJan 2026 onwardDivest EUR 300 m of Belgian residential care centres in Flanders and Wallonia over several years to a qualifying buyerPending; no 2026 rental impact expected
Exit from SwedenQ1 2025Sale of 22 care centres plus education assets (~EUR 93 m)Completed
Financing platform for combined entityH1 2026EUR 620 m sustainability-linked syndicated RCF (8 banks, 5 years, 2×1-year extensions, EUR 100 m accordion); EUR 930 m total long-term bank (re)financing; treasury notes programme raised from EUR 600 m to EUR 1.5 bnCompleted
Investment-grade upliftMar and Oct 2026S&P upgrade to BBB+; Moody's first-time A3Completed
Potential bond issuanceAutumn 2026Management indicated a possible bond issue in autumn, compatible with EUR 5.35 EPS guidance (H1 2026 call)Unconfirmed
Armonea/Colisée agreementsEarly 2026Property-specific agreements during Colisée's financial recovery plan; Klein Veldekens campus transferred to Vulpia (July 2026)Ongoing
Office repositioning2,026M10 lease at prime rent; 30-year NATO NCIA usufruct for Bourget 40; Egmont I & II bare-ownership saleExecuted

Medium-term targets and guidance

ItemTarget / guidanceSource
FY2026 rental incomeEUR 656 mH1 2026 report
FY2026 EPRA EarningsEUR 436 mH1 2026 report
FY2026 EPRA EPSEUR 5.35 (+4% y/y); management sees upside potentialH1 2026 report and call
FY2026 gross DPSEUR 4.20 (+5%)H1 2026 report
Average cost of debt 2026~1.9%H1 2026 report
Debt-to-assets year-end 2026~42%H1 2026 report
Run-rate synergies≥EUR 16 m during 2027H1 2026 report
Development yield on cost6–6.5%H1 2026 report
Pipeline size targetEUR 500–750 mH1 2026 call (Alpha Spread summary)
Energy intensity130 kWh/m² by 2030Environmental Data Report (June 2026)

Products & Services

For a REIT, "products" are asset classes and lease offerings. The catalogue below is organised by segment and country.

Healthcare real estate: by asset type

Asset typeDescriptionTarget customerShare of total portfolio FV (30.06.2026)Lease model
Elderly care homes (nursing and care homes)Residential care centres with 24h nursing carePrivate and non-profit care operators (Clariane, Colisée/Armonea, Emeis, DomusVi, Emera, Vulpia, Azurit Rohr, etc.)60%15–30-year NN/NNN leases, CPI-indexed
Mixed-use elderly careCampuses combining care home, assisted living and service flatsSame operators; German "Seniorenquartier" concepts13%Long leases
Cure centresSpecialised acute, rehabilitation and psychiatric clinics (mainly France and Belgium, from Cofinimmo)Clinic operators, e.g. Clariane, French Red Cross7%Long leases (France WAULT ~7 years)
Childcare centresDay-care centres (Finland)Private operators (Touhula, Pilke, Norlandia) and municipalities3%15–20-year NN
Senior housingIndependent and assisted living apartmentsOperators and housing associations2%Long leases
Disabled care facilitiesResidential care for physical and mental impairmentsEsperi, Finnish foundations, municipalities2%15–20-year NN
Other care propertiesMedical office buildings, sport and wellness (e.g. Aspria/David Lloyd), cancer centre (Limerick)Specialist operators2%Long leases

Healthcare real estate: by country (30.06.2026)

CountrySitesSurface (m²)ResidentsChildrenFair value (EUR Mn)Contractual rent (EUR Mn)Gross yieldKey operators
Belgium1591,068,88418,246—2,784.0166.86.0%Korian (Clariane), Armonea (Colisée), Vulpia, Care-Ion, Orelia, Emeis, Vivalto
Germany156995,71216,177—2,079.0118.35.7%Azurit Rohr, Residenz Management (Specht), Stella Vitalis, Emeis, Vitanas, Compassio, Alloheim
Netherlands111537,8314,637—1,197.676.06.3%Korian NL, Martha Flora (DomusVi), Stichting Tantelouise, NNCZ
United Kingdom119358,8337,803—1,356.4 (GBP 1,168.7 m)87.46.4%Maria Mallaband, Bondcare, North Bay Group, Welltower, Emera
Finland251383,4885,45512,9471,429.785.46.0%Municipalities/wellbeing counties, Attendo, Mehiläinen, Norlandia, Esperi, Touhula, Pilke
Ireland30147,9932,879—549.531.35.7%Bartra, Emera, DomusVi
Spain37240,3195,757—429.823.75.5%Emera, DomusVi, Reifs, Amavir, Vivalto, Neurocare Home
France53308,8945,092—664.343.56.6%Clariane, French Red Cross, DomusVi, Emeis
Italy875,8731,337—215.912.35.7%KOS, Clariane
Healthcare total9244,117,82867,38312,94710,706.2644.76.0%—

Source: Aedifica H1 2026 report, Section IV.3.1. GBP converted at 0.86161 EUR/GBP.

Offices (legacy Cofinimmo)

ItemDetail
Portfolio23 sites, 248,336 m², fair value EUR 874.4 m, contractual rent EUR 55.0 m, gross yield 6.3% (30.06.2026)
Location~72–75% Brussels CBD (Leopold/European quarter); public-sector tenants ~42% of office rent (Cofinimmo FY2025)
FlagshipM10 (Montoyer 10), Brussels CBD, delivered July 2024. BREEAM New Construction Outstanding (Apr 2025), WELL Core Platinum (Sep 2025); new lease signed Q2 2026 at prime rent of ~EUR 400/m²/year; occupancy 57% after that lease
Long-lease public assetStationsstraat 110, Mechelen: ~15,000 m², renovated, 18-year lease to the Flemish Community's Facilitair Bedrijf (delivered Jan 2025)
Long-term usufructBourget 40 (~14,300 m², part of Leopold Square complex opposite NATO HQ): 30-year usufruct agreement signed in 2026 with the NATO Communications and Information Agency
RedevelopmentsLoi/Wet 85 and Loi/Wet 89 (Brussels CBD) in redevelopment at end-2025
Recent disposalEgmont I & II bare ownership sold (July 2026; ~EUR 16 m office component of a EUR 27 m post-H1 disposal package)
OccupancyOffices 92.8% (Cofinimmo FY2025)

Distribution networks (legacy Cofinimmo)

ItemDetail
Pubstone Belgium577 pubs/restaurants leased to AB InBev (3% of group rent)
Pubstone Netherlands185 pubs leased to AB InBev (2% of group rent)
Other – BelgiumTenreuken land reserve (Brussels) and federal police station at Kroonveldlaan 30, Dendermonde
Totals (30.06.2026)776 sites, 276,700 m², fair value EUR 467.9 m, rent EUR 34.8 m, gross yield 7.4%
Rotation27 pubs sold in 2025 for EUR 9 m (above fair value); 12 pubs in H1 2026 and 2 more in Q3 2026

Public-private partnerships (legacy Cofinimmo)

Six PPP contracts for special-use buildings in Belgium, such as police stations, booked as finance leases (five in Cofinimmo SA/NV, one in FPE Leuze SA/NV). The Edegem police station (HEKLA zone) was sold in 2025 for ~EUR 7 m, a EUR 3 m gain over carrying value. Group finance-lease receivables were EUR 181.6 m non-current and EUR 5.0 m current at 30.06.2026 (after PPA remeasurement).

Development offering (investment programme, 30.06.2026)

Completion yearBudget (EUR Mn)Examples
2,026217 (projects) + 33 (forward purchases)Genappe (Korian BE), NRW eco-campus (Compassio), Finnish elderly-care pipeline, Limerick cancer centre (UPMC & Bon Secours), Alicante and Castellón (Vivalto), Gevita Residenz Lörrach (Argentum), Sinnehiem (NL)
2,027207 + 15Seniorenquartier Gummersbach (Specht), Crumlin (Bartra), Kilcoole (Muskerry), Córdoba and Oviedo (Amavir), Ourense and Tenerife (DomusVi), Seville (Reifs), Homefield (Emera)
2,02843Stadtlohn (Specht), Palma de Mallorca (Emera)
2,03017Coham (Clariane, Belgium)
Total531 (EUR 268 m spent, EUR 263 m to go)Average initial yield on cost ~5.8%

Source: Aedifica H1 2026 report, Section IV.3.2.

Pricing model: Rents are set as an initial yield on cost or acquisition value (new developments target 6–6.5%) and indexed annually to local CPI. Individual lease rents are not disclosed.

Financial Narrative

Framework note: REITs do not report "revenue/gross profit/EBITDA" in the industrial sense. The closest equivalents are: revenue = rental income; gross profit ≈ property result after direct property costs; operating income = operating result before result on portfolio; recurring earnings = EPRA Earnings (Cofinimmo: "net result from core activities – group share"). Because the successor entity changed in 2026, tables are presented for both companies.

Legacy Cofinimmo: income statement and KPIs

Sources: Cofinimmo FY2021, FY2022, FY2023, FY2024 and FY2025 annual results releases. FY2025 EPRA Earnings exclude merger-related non-recurring effects (net expense EUR 1.4 m).

EPRA Earnings CAGR FY2021–FY2025 (derived): (245.6/212)^(1/4) − 1 ≈ 3.7%. Per share, EPRA EPS fell from EUR 7.15 to EUR 6.45 (≈ −2.5% CAGR, derived), because equity issuance (EUR 565 m in 2021, 114 m in 2022, 247 m in 2023, 75 m in 2024) and disposals diluted per-share growth. Cofinimmo quantified the FY2025 dilution at −EUR 0.29/share from divestments and −EUR 0.10/share from capital increases.

Legacy Cofinimmo: balance sheet

Source: Cofinimmo FY2025 release (balance sheet 31.12.2025 vs 31.12.2024); FY2022 and FY2023 releases for debt ratios. Structurally negative working capital reflects ~EUR 750 m of short-term sustainable commercial paper, fully backed by undrawn committed long-term lines (headroom EUR 1,031 m after backup at 31.12.2025).

Legacy Cofinimmo: cash flow items

Operating cash flow, free cash flow and dividends paid in cash were not captured in this research. Buybacks: none; treasury share movements relate only to stock-option plan delivery (11,398 treasury shares at 31.12.2025).

Aedifica (successor): income statement and KPIs

Sources: Aedifica financial information page (income statement excerpts FY2023–FY2025); FY2025 annual results press release (13.02.2026). The FY2024 DPS of EUR 3.90 is derived from the disclosed 2.6% increase to EUR 4.00. Rental income CAGR FY2023–FY2025 (derived): 7.2%.

Combined group: H1 2026 snapshot (first period including Cofinimmo)

Source: Aedifica H1 2026 report. The bargain purchase gain (badwill) of EUR 316.1 m arose because the fair value of the Aedifica shares issued was below Cofinimmo's PPA-adjusted net equity; the Q1 2026 release had shown EUR 314.4 m before final adjustment. PPA remeasurements: financial debt +EUR 86.6 m and finance-lease receivables +EUR 30.5 m, amortised over instrument lives (EUR 8.6 m in H1 2026, non-cash).

Commentary on trends, inflections and drivers

1. Earnings plateau versus per-share erosion (Cofinimmo, 2021–2025). Cofinimmo grew absolute recurring earnings modestly (EUR 212 m to EUR 246 m) through heavy healthcare investment financed partly with equity, while selling offices. The model diluted per-share earnings once interest rates rose and the shares traded below NAV. A capital-recycling strategy (about EUR 700 m divested in 2022–2024 and close to EUR 1 bn of office net divestments since 2005) protected the balance sheet but compressed EPS. This culminated in the February 2025 dividend cut from EUR 6.20 to EUR 5.20. The cut, in turn, left Cofinimmo exposed to Aedifica's approach three months later.

2. Valuation cycle. Both companies took fair-value losses in 2023: Cofinimmo's portfolio fell 1.7% in 2023 and 1.9% in 2024 like-for-like, and Aedifica booked −EUR 143.6 m in 2023. The cycle turned in Q1 2025, ending nine consecutive quarters of declines at Cofinimmo. Aedifica recorded six consecutive positive quarters through Q2 2026 (+0.35% like-for-like year-to-date). This drove the IFRS EPS recovery at Aedifica (EUR 0.56 → 4.31 → 5.14).

3. Merger arithmetic. Aedifica guides FY2026 rental income of EUR 656 m (+82% vs FY2025's EUR 361 m) and EPRA EPS of EUR 5.35 (+4%). Accretion comes from Cofinimmo's lower cost of debt (1.5% vs Aedifica's 2.1%), EUR 5.5 m of 2026 synergies (rising to ≥EUR 16 m run-rate during 2027), and the exchange ratio, which priced Cofinimmo at a discount to its NTA. The headline H1 2026 net profit of EUR 509.6 m is dominated by the non-cash badwill and should be excluded from any ROE analysis.

4. Leverage drift. Group debt-to-assets rose from 40.8% to 42.7% on consolidation (Cofinimmo ran ~43%). Management targets the low-40s and around 42% at year-end 2026, below the self-imposed 45% ceiling and far below the 65% RREC legal cap. Net debt/EBITDA of 8.3x is elevated in absolute terms but typical for long-lease European healthcare REITs.

5. Cost of debt is the medium-term headwind. Cofinimmo had disclosed that its average cost of debt would gradually rise toward about 2.3% by 2028 as hedges roll off; its hedge coverage was scheduled to fall from 100% (end-2025) to 71% (end-2029). Aedifica's group hedge ratio of 89.6% has a weighted maturity of only 3.4 years. Rising funding costs are therefore a structural drag that synergies and indexation must offset.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment

SegmentH1 2025H1 2026

Healthcare real estate rental income (EUR Mn)

180.8266.3

Offices rental income (EUR Mn)

015.4

Distribution networks rental income (EUR Mn)

010.6

Total rental income (EUR Mn)

180.8292.3

Revenue by Segment

SegmentFY2024FY2025

Healthcare gross rental revenues (EUR Mn)

264.0266.9

Offices gross rental revenues (EUR Mn)

59.952.9

Distribution networks gross rental revenues (EUR Mn)

34.634.9

Total gross rental revenues (EUR Mn)

358.5354.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Revenue

SegmentReported change FY2025Like-for-like FY2025

Healthcare

+1.1%+2.8%

Offices

−11.7%+2.8%

Distribution networks

+0.8%+3.2%

Total

−1.1%+2.9%

Segment Overview

SegmentFair value (EUR K)% of portfolioNet rental income (EUR K)Property result after direct costs (EUR K)Segment margin (derived: PRADC / NRI)

Healthcare real estate

4,680,78176.9%258,439247,96995.9%

Offices

925,47615.2%55,63752,75194.8%

Distribution networks

478,7987.9%34,11531,83593.3%

Total

6,085,055

100%

348,191

332,554

95.5%

Segment Overview — Healthcare BE + FR

SegmentGross rental yield at 100% occupancyNet rental yield at 100% occupancy

Healthcare BE + FR

5.9%5.9%

Healthcare DE + NL

5.6%5.0%

Healthcare ES + FI + IE + IT + UK

5.4%5.0%

Offices

6.4%5.8%

Distribution networks

6.7%6.3%

Total

5.9%5.6%

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Gross rental revenues (EUR Mn)

———358.5354.7

Rental income net of rental-related expenses (EUR Mn)

———350.9347.6

Property result (EUR Mn)

———345.3344.3

Property result after direct property costs (EUR Mn)

———331.6332.6

Corporate management costs (EUR Mn)

———-44.7-45.0

Operating result before portfolio result (EUR Mn)

———286.8287.6

Net interest charges (EUR Mn)

———-39.5-37.6

EPRA Earnings / net result core activities group share (EUR Mn)

212222241243.8245.6

Net result group share (EUR Mn)

—483-5563.9213.5

EPRA EPS (EUR)

7.15——6.506.45

Net result group share per share (EUR)

———1.705.61

Gross dividend per share (EUR)

6.006.206.206.205.20

Operating margin (%)

———83.183.5

EPRA Earnings margin on gross rents (%, derived)

———68.069.2

Net margin on gross rents (%, derived)

———17.860.2

Balance Sheet and Margin Analysis (%)

MetricFY2021FY2023FY2024FY2025

Investment properties at fair value (EUR Mn)

——5,9946,085

Total assets (EUR Mn)

——6,440.06,437.9

Cash and equivalents (EUR Mn)

——25.823.8

Non-current financial debt (EUR Mn)

——1,753.31,588.5

Current financial debt (EUR Mn)

——834.1999.7

Total financial debt (EUR Mn)

——2,587.32,588.2

Net financial debt (EUR Mn, derived)

——2,561.52,564.4

Total equity incl. minorities (EUR Mn)

——3,614.43,590.1

Equity attributable to parent (EUR Mn)

——3,535.03,511.3

Goodwill (EUR Mn)

——00

Intangible assets (EUR Mn)

——1.81.5

Working capital (current assets minus current liabilities, EUR Mn, derived)

——-834.9-1,041.1

Debt-to-assets ratio (%)

44.243.842.642.8

EPRA LTV (%)

——42.241.9

IFRS NAV per share (EUR)

——92.8492.20

EPRA NTA per share (EUR)

——93.1192.99

Average cost of debt (%)

1.1—1.41.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

EPRA capex (investment properties, EUR Mn)

———140131

Gross investments (EUR Mn)

————111

Divestments (EUR Mn)

————82

Net investments (EUR Mn)

——-1—29

Capital increases (EUR Mn)

565114247750

Key Financials and Per-Share Data

MetricFY2023FY2024FY2025

Rental income (EUR Mn)

314.2338.1361.0

Net rental income (EUR Mn)

313.0338.0360.5

EPRA Earnings (EUR Mn)

—234.6244.8

EPRA EPS (EUR)

5.024.935.15

Basic and diluted IFRS EPS (EUR)

0.564.315.14

Change in fair value of investment properties (EUR Mn)

-143.615.275.4

Change in fair value of financial instruments (EUR Mn)

-50.9-18.7-9.6

Gross dividend per share (EUR)

—3.904.00

EPRA Earnings margin on rental income (%, derived)

—69.467.8

Key Financials and Margin Analysis (%)

MetricFY2023FY2024FY2025

Real estate portfolio fair value (EUR Mn)

——6,285

Debt-to-assets ratio (%)

—41.340.8

EPRA LTV (%)

——39.7

EPRA NRV per share (EUR)

84.1786.4687.09

EPRA NTA per share (EUR)

74.1876.6378.40

EPRA NDV per share (EUR)

75.4177.1977.73

EPRA vacancy rate (%)

0.10.10.1

Net debt / EBITDA (x)

——7.8

Average cost of debt incl. commitment fees (%)

——2.1

Balance Sheet and Margin Analysis (%) (Half-Yearly)

MetricH1 2025H1 2026Change

Rental income (EUR Mn)

180.8292.3+62%

Net rental income (EUR Mn)

180.6293.3+62%

Operating charges (EUR Mn)

-24.2-39.2—

Operating result before portfolio result (EUR Mn)

156.5254.1+62%

EBIT margin (%)

86.6

86.6 (≈85.5 normalised)

flat

Financial result excl. FV changes (EUR Mn)

-27.1-37.5—

Corporate tax (EUR Mn)

-5.5-8.0—

Non-controlling interests in EPRA Earnings (EUR Mn)

-0.3-18.9—

EPRA Earnings (EUR Mn)

123.3189.9+54%

EPRA EPS (EUR)

2.592.71+5%

Goodwill impairment, PPA amortisation and badwill (EUR Mn)

0+307.5—

Profit attributable to owners (EUR Mn)

113.1509.6—

IFRS EPS (EUR)

2.387.28—

EPRA cost ratio incl. vacancy (%)

13.513.1—

Balance sheet / leverage

31.12.2025

30.06.2026

—

Investment properties incl. held for sale (EUR Mn)

6,28512,478—

Total assets (EUR Mn)

6,47713,083—

Equity incl. NCI (EUR Mn)

3,6697,216—

Non-controlling interests (EUR Mn)

5.6799.5—

Liabilities in debt-to-assets ratio (EUR Mn)

2,6245,544—

Drawn on credit lines (EUR Mn)

2,4855,256—

Goodwill (Hoivatilat, EUR Mn)

—59.7—

Debt-to-assets (%)

40.842.7—

EPRA LTV (%)

39.742.2—

Interest cover ratio (x)

6.27.6—

Net debt / EBITDA (x)

7.88.3—

Hedge ratio (%)

88.389.6—

Average cost of debt incl. fees (%)

2.11.9—

IFRS NAV per share (EUR)

77.0576.87—

EPRA NTA per share (EUR)

78.4077.82—

Financial Analysis

RatioCofinimmo FY2024Cofinimmo FY2025Aedifica FY2025Aedifica H1 2026

ROE (net result group share / avg parent equity)

~1.8% (derived)

~6.1% (derived)

not computed

not meaningful (badwill-inflated)

ROA (net result / avg total assets)

~1.1% (derived)

~3.4% (derived)

not computed

not meaningful

Current ratio (x)

0.14 (derived)

0.09 (derived)

not computed

not computed

Debt/equity (financial debt / total equity)

0.72 (derived)

0.72 (derived)

not computed

~0.73 (derived, drawn debt / equity)

Net debt / EBITDA (x)

~8.9 (derived, operating result as EBITDA proxy)

~8.9 (derived)

7.8 (reported)

8.3 (reported)

Interest coverage (operating result / net interest)

~7.3x (derived)

~7.6x (derived)

6.2x (reported ICR)

7.6x (reported ICR)

Asset turnover (gross rents / avg assets)

~5.6% (derived)

~5.5% (derived)

not computed

not computed

Cash conversion cycle

not applicable to REITs

not applicable

not applicable

not applicable

Revenue by Region

Country / segmentH1 2025H1 2026

Belgium healthcare (EUR Mn)

36.365.3

Germany healthcare (EUR Mn)

32.249.1

Netherlands healthcare (EUR Mn)

20.631.5

United Kingdom healthcare (EUR Mn)

45.143.0

Finland healthcare (EUR Mn)

34.738.4

Ireland healthcare (EUR Mn)

11.914.2

Spain healthcare (EUR Mn)

0.17.5

France healthcare (EUR Mn)

013.5

Italy healthcare (EUR Mn)

03.8

Belgium offices (EUR Mn)

015.4

Belgium and Netherlands distribution networks (EUR Mn)

010.6

Total (EUR Mn)

180.8292.3

Country

Reported change (local currency)

Like-for-like change

Belgium

+79.9%+1.6%

Germany

+52.3%+2.1%

Netherlands

+53.0%+5.1%

United Kingdom

−4.6%+5.0%

Finland

+10.7%+0.4%

Ireland

+19.8%+2.1%

Spain

+8,615%+3.4%

France

new

+0.4%

Italy

new

−0.8%

Offices

new

−1.3%

Distribution networks

new

+2.6%

Total

+61.6%

+1.7%

Geographic Revenue

CountryAedifica 31.12.2025 (EUR Mn)Combined 30.06.2026 (EUR Mn)Share of total, 30.06.2026

Belgium (all segments)

1,255

4,126 (healthcare 2,784 + offices 874 + ~468 distribution, Belgian share partly Dutch)

33% (incl. offices and distribution)

Germany

1,1902,07917%

Finland

1,2341,43012%

United Kingdom

1,2531,35611%

Netherlands

694

1,198 (healthcare)

11% (incl. Pubstone NL)

France

06645%

Ireland

4335505%

Spain

344304%

Italy

02162%

Country Overview

CountryFair value (EUR Mn)% of portfolioNet rental income (EUR Mn)SitesHealthcare WAULT (years)

Belgium healthcare

1,596.526.2%86.08316

France

666.911.0%44.1537

Netherlands

486.98.0%31.24310

Germany

935.715.4%49.95918

Spain

444.77.3%

47.3 (ES+FI+IE+IT+UK combined)

3120

Finland

165.92.7%

(incl. above)

1616

Ireland

100.41.7%

(incl. above)

812

Italy

216.03.5%

(incl. above)

85

United Kingdom

67.81.1%

(incl. above)

331

Offices (Belgium)

925.515.2%55.625—

Distribution networks (BE/NL)

478.87.9%34.1——

Capital Markets Data (EUR) and Margin Analysis (%)

MetricFY2023FY2024FY2025

Cofinimmo year-end share price (EUR)

71.4055.6079.20

Cofinimmo 12-month high (EUR)

90.0071.6579.45

Cofinimmo 12-month low (EUR)

54.1552.1551.80

Cofinimmo gross total return (%)

-8.0-14.154.4

Cofinimmo market cap year-end (EUR Mn)

2,6252,1183,017

Cofinimmo dividend yield on average price (%)

8.310.17.4

Aedifica year-end share price (EUR)

——67.50

Aedifica Price Point Details

Aedifica price pointValueSource

31.12.2025 close

EUR 67.50

H1 2026 report

H1 2026 range

EUR 66.50 – 80.05

H1 2026 report

30.06.2026 close

EUR 70.60 (+~5% YTD at that date)

H1 2026 report

13–18 Oct 2026

EUR 61.13 – 62.83 (Lang & Schwarz)

Secondary news source

YTD to ~18.10.2026 (derived)

≈ −7.7% price return

Derived

Since IPO to 30.06.2026

+108.7% price; total return +361%

H1 2026 report

Valuation Snapshot

MultipleValueBasis

P/EPRA Earnings (2026e)

~11.6x

EUR 5.35 guidance

Dividend yield (2026e)

~6.7%

EUR 4.20

P/EPRA NTA

~0.80x (~20% discount)

EUR 77.82 (30.06.2026)

P/IFRS NAV

~0.81x

EUR 76.87

EV/Sales (2026e rental)

~16.8x

Market cap ~EUR 5.77 bn plus drawn debt EUR 5.26 bn, divided by EUR 656 m; excludes cash and minorities

EV/EBITDA

Not computed (FY EBITDA not guided)

—

Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Cofinimmo gross DPS (EUR)

6.006.206.206.205.20

Aedifica gross DPS (EUR)

———3.904.00

Credit Ratings

AgencyRatingOutlookDate / notes

S&P Global

BBB+ long-term; A-2 short-term

Stable

Upgraded from BBB on 13.03.2026; reconfirmed 20.07.2026

Moody's

A3 issuer (first-time), also covering ~EUR 1.5 bn senior unsecured notes

Stable

Reported 15.10.2026 by secondary sources. One source notes Aedifica's IR page shows the A3 dated 10.09.2026; the discrepancy is unresolved

Fitch

Not rated (not identified)

——

Legacy Cofinimmo (S&P)

BBB / A-2, positive watch

—

Rated by S&P since 2001; confirmed 25.03.2025

Maturity Year Details

Maturity yearCommitted lines (EUR Mn)Utilisation (EUR Mn)Short-term treasury notes (EUR Mn)
20261221121,003
202799083280
20281,6431,1840
20295633320
20301,4529320
20311,6686710
203295500

After 2032

2991490

Total

6,8324,2621,083

Bond Details

BondNominalCouponMaturityISIN

Straight bond 2016–2026

EUR 70 m

1.70%

26.10.2026

BE0002267368

Sustainable bond 2022–2028

EUR 500 m

1.00%

24.01.2028

BE0002838192

Sustainable bond 2020–2030

EUR 500 m

0.875%

12.02.2030

BE6325493268

Margin Analysis (%)

Hedge component2026H12026YE2027YE2028YE2029YE

Fixed-rate debt (% of projected debt)

3937352221

Swaps (% of projected debt)

5151454028

Unhedged floating (% of projected debt)

1012203851

Analyst Conclusions

Management guidance (FY2026)

Rental income of EUR 656 m; EPRA Earnings of EUR 436 m; EPRA EPS of EUR 5.35 (+4%), with management flagging possible upside; gross DPS of EUR 4.20 (+5%); average cost of debt ~1.9%; debt-to-assets ~42% at year-end; disposals of EUR 110 m (EUR 54 m done); synergies of EUR 5.5 m in 2026, rising to ≥EUR 16 m run-rate during 2027. The Belgian EUR 300 m remedy sale is not expected to affect 2026 rental income. The guidance assumes 0.8695 EUR/GBP for H2 2026.

Consensus expectations

FY2026 EPRA EPS consensus is ~EUR 5.33 (cited at the H1 call). Analytically, FY2027 should benefit from full-year consolidation, at least EUR 10 m of incremental synergies (≈ +EUR 0.11/share, derived) and pipeline deliveries (~EUR 222 m due in 2027). These are offset by rising hedge roll-off costs and a full year of the larger share count.

Bull case

  1. Accretive platform with upside to synergies: H1 2026 EPS +5% before most synergies, a 0.80x P/NTA entry point and ~6.7% yield. Delivering ≥EUR 16 m synergies plus indexation could sustain mid-single-digit EPS growth.

  2. Credit re-rating lowers the cost of capital: BBB+ and A3 ratings support cheap unsecured bonds to term out EUR 1.1 bn of treasury notes, protecting the ~1.9% debt cost as Cofinimmo-legacy hedges expire.

  3. Operator recovery drives values: rising operator occupancy (+232 bps in Germany, +247 bps in the Netherlands) and rent covers (UK 2.3x) underpin six straight quarters of valuation gains, which could close the NAV discount.

Bear case

  1. Refinancing cliff: unhedged floating debt rises from 10% to 51% of projected debt by 2029. With 8.3x net debt/EBITDA, each 100 bps rise in rates on newly unhedged debt would be a material EPS headwind.

  2. Tenant concentration and operator fragility: Clariane (12%) and Colisée/Armonea (7%) remain exposed to wage inflation and staffing shortages. Any renewed operator distress would hit both rents and valuations.

  3. Contingent liabilities and forced sales: up to ~EUR 108 m of German and Dutch transfer taxes, a EUR 300 m Belgian sale with constrained buyer pool, and non-core offices (M10 57% let) could dilute NAV and earnings.

Key catalysts and monitorables (next 12 months)

TimingCatalyst
26.10.2026Repayment/refinancing of the EUR 70 m 1.70% legacy Cofinimmo bond
Autumn 2026Possible inaugural combined-entity unsecured bond (post-Moody's A3)
18.11.2026Q3 2026 results: synergy tracking, guidance confirmation or raise
H2 2026 – 2027Dutch Tax Authority ruling on merger exemption (~EUR 63.4 m); German RETT position (~EUR 45 m)
2026–2027Announcement of the buyer and pricing for the EUR 300 m Belgian remedy portfolio
17.02.2027FY2026 results and FY2027 guidance (first full-year combined outlook)
2,027Full ≥EUR 16 m synergy run-rate; delivery of EUR 222 m of pipeline projects
OngoingOffice disposals and leasing (M10, Loi 85/89 redevelopments); Pubstone rotation
OngoingColisée/Armonea performance post-restructuring; Clariane credit
11.05.2027AGM; payment of the EUR 4.20 FY2026 dividend

Analyst verdict

Cofinimmo as a listed equity is gone. Its legacy lives on inside a materially stronger Aedifica, and the investment question now is whether the combined group can convert scale into durable per-share growth. The first evidence is encouraging. H1 2026 EPRA EPS rose 5% to EUR 2.71 before most synergies, and FY2026 guidance of EUR 5.35 sits marginally above consensus. Both rating agencies now place the group comfortably in investment grade (BBB+ / A3). The operating base is defensive: a 15-year WAULT, 99.1% occupancy, CPI-indexed rents across nine countries, and a demographic tailwind that every market review in the company's own reporting describes as structural.

Against this, the balance sheet is fuller than at end-2025. Net debt/EBITDA is 8.3x and debt-to-assets 42.7%, and the hedge book thins sharply after 2027. Earnings growth beyond 2027 therefore depends on three things: synergies, development deliveries at 6%-plus yields, and refinancing discipline, chiefly terming out more than EUR 1 bn of treasury notes into bonds at a sensible spread. The inheritance from Cofinimmo also brings unwanted baggage: about 11% of value in offices and pubs, legacy Spanish and German development disputes, two transfer-tax contingencies totalling up to ~EUR 108 m, and a regulator-mandated EUR 300 m Belgian sale.

At ~EUR 62, the shares trade around 0.80x EPRA NTA, ~11.6x 2026e EPRA earnings and a ~6.7% prospective yield. That pricing already discounts much of the refinancing and concentration risk. The decisive monitorables are the Q3 and FY2026 prints, the Dutch tax ruling, and evidence that non-core disposals and remedy sales can be executed near book value. Failure on these points would turn the NAV discount from an opportunity into a verdict.


Principal sources consulted

  • Aedifica SA/NV: 2026 Half Year Financial Report (01.09.2026); Q1 2026 interim report and slides (19.05.2026); FY2025 annual results press release (13.02.2026); legal merger completion release (01.07.2026); new Board / share issuance release (10.03.2026); merger proposal release (30.04.2026); Board merger report (04.05.2026); executive CVs (Daerden, van Aelst, Bicici, Dumont); financial information web page.

  • Cofinimmo SA/NV: FY2025 annual results (20.02.2026); FY2024, FY2023, FY2022 and FY2021 annual results; H1 2022, Q3 2022, Q1–Q3 2024 releases; Q1 2026 release (22.04.2026); EGM merger approval release (30.06.2026); change-of-control release (10.03.2026); roadshow presentations 2022–2024; investor reports page.

  • Belgian Competition Authority: press release No. 2/2026 (21.01.2026).

  • Secondary and market sources (flagged in text): Stibbe, manda.be, La Libre Belgique, Bolero/KBC Securities, Alimarket, MLex, LaingBuisson, CB Insights, Parqet, Quartr, Alpha Spread, Investing.com, RTTNews, Zonebourse/Fortuneo, MarketScreener, AD HOC NEWS, roic.ai, Real Asset Insight, CRE Herald, earnings call transcripts (Cofinimmo FY2024 and FY2025; Aedifica FY2025 and H1 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure in rolePrior roles / backgroundEducationBirth year

Stefaan Gielens

CEO and Executive Director (only executive on the board)

Since Aedifica's early years (2006 per aggregator)

Founding CEO of Aedifica

Not captured

~1965 (aggregator age 61)

Ingrid Daerden

Chief Financial Officer

Since September 2018

~10 years real-estate finance at ING Belgium; Cofinimmo 2008–2016 (Investor Relations Manager, then Head of Treasury & Project Finance); CFO of OTN Systems

Master in Business Engineering, KU Leuven

1974

Charles-Antoine van Aelst

Chief Investment Officer

CIO since October 2017; ExCo since June 2020

Joined Aedifica in 2008 as Corporate Analyst/IR; Investment Manager (2011); Investment Officer (2016)

Master of Applied Economics (Antwerp); Master of Financial Management (Vlerick); Postgraduate Certificate in Real Estate (KU Leuven)

1986

Yeliz Bicici

Chief Operating Officer

Since July 2026

Cofinimmo 2008–2026: Property Manager, Area Manager, Development Manager, Head of Development (2014), COO (July 2018); earlier Robelco (2001–2008) and Uniway

Dual Master in Real Estate (KU Leuven 2009; Antwerp Management School 2012); Harvard Business School GMP (2021); postgraduate energy engineering and financial analysis (Ghent)

1976

Roel Dumont

Chief Human Resources Officer

Since July 2026

Alken-Maes Breweries HR (2000–2008); Tessenderlo Group global HR roles incl. VP HR (13 years); labour court judge since 2007; Cofinimmo ExCo member for HR and internal communication from 2021

Master in Law (KU Leuven); business administration (EMS)

1973

Sven Bogaerts

Chief M&A Officer / General Counsel (per aggregator; current ExCo title not confirmed)

General Counsel role from June 2020 (aggregator)

Previously Eubelius (law firm) per aggregator

Not captured

~1978 (aggregator)

Board of Directors

NameRoleOriginCommittees (where disclosed)

Jean Hilgers

Chair (from 01.07.2026; Vice-Chair 10.03–30.06.2026)

Cofinimmo (former Chair)

Chair of the Nomination and Remuneration Committee (from March 2026)

Serge Wibaut

Independent Director (Chair until 30.06.2026)

Aedifica

Not captured

Stefaan Gielens

Executive Director, CEO

Aedifica

—

Ann Caluwaerts

Independent Director

Cofinimmo

Nomination and Remuneration Committee

Nathalie Charles

Independent Director

Cofinimmo

Audit and Risk Committee

Xavier de Walque

Independent Director

Cofinimmo

Audit and Risk Committee

Fifth Cofinimmo-origin director

Independent Director

Cofinimmo

Name not captured in this research

Marleen Willekens

Independent Director (since 2017, aggregator)

Aedifica

Not captured

Elisabeth May-Roberti

Independent Director (since 2015, aggregator)

Aedifica

Not captured

Ms van Velthuizen-Lormans

Independent Director (aggregator listing)

Aedifica

Not captured

Remaining Aedifica-origin director

Independent Director

Aedifica

Not captured

Major Shareholders

ShareholderStakeDate / source

BlackRock, Inc.

5.79% (4,829,214 voting rights)

Notified 12.03.2026; on 83.47m shares

Stichting Pensioenfonds ABP

5.13% (4,281,807) → 4.76% (4,411,528 on enlarged base)

Notified 02.06.2026 and 01.07.2026

Others below 5%

~89–90%

Aedifica H1 2026 report

Free float (Euronext definition)

100%—

Treasury shares

855

30.06.2026

Competitive Landscape

Key Competitors

CompetitorSegment overlapPositioning vs Aedifica

Welltower (US)

UK and pan-European care homes; also an Aedifica tenant (15 UK sites)

Global giant with operating platforms; competes for large UK deals; much larger cost of capital advantage in USD markets

Care Property Invest (BE)

Belgian and Dutch/Spanish care homes

Smaller Belgian REIT; now Belgium's #2 pure-play healthcare REIT after the merger

Primary Health Properties (UK; merged with Assura in 2025)

UK and Irish primary-care/medical property

Adjacent segment (GP surgeries) rather than care homes

Target Healthcare REIT (UK)

UK care homes

Smaller UK specialist

Impact Healthcare REIT (UK)

UK care homes

Smaller UK specialist

Praemia Healthcare (formerly Icade Santé, FR)

French clinics and nursing homes, expanding in Europe

Main French/Italian rival for Cofinimmo-legacy assets

Hemsö (SE) / Nordic players

Nordic social infrastructure

Competes in Finland

Healthcare Activos (ES/PT)

Spanish care homes

Spanish competitor

Nrep / unlisted funds (e.g. Nordic care JV)

Finnish care homes (a EUR 400 m Finnish JV reported in 2025)

Private capital competitor

Omega Healthcare / Sabra (US)

UK care homes

US REITs active in UK

Brussels office landlords (e.g. AG Real Estate / Befimmo, Allianz, Axa IM)

Brussels CBD offices

Competition for public and EU-institution tenants

Competitor Detail

MetricAedifica (combined)

Rental income

EUR 656 m (FY2026 guidance)

Portfolio value

EUR 12.5 bn

Recurring EPS growth

+4% (2026e)

EBIT margin

86.6% (H1 2026)

R&D intensity

n/a (real estate)

Credit rating

BBB+ (S&P) / A3 (Moody's)

Company Snapshot

127

Employees

1983

Founded

Brussels, Belgium

Headquarters

SWOT Analysis

Strengths

  • Scale leadership: EUR 12.5 bn portfolio and 1,723 properties at 30.06.2026, roughly double Aedifica's EUR 6.3 bn at end-2025.
  • Contractual visibility: 15-year WAULT (healthcare 16 years) and 99.1% occupancy (EPRA vacancy 0.9%).
  • Funding-cost advantage: 1.9% average cost of debt incl. fees, 89.6% hedged; S&P BBB+ and Moody's A3.
  • Immediate accretion: H1 2026 EPRA EPS +5% to EUR 2.71; FY2026 guided +4% to EUR 5.35, slightly above the EUR 5.33 consensus cited at the H1 call.
  • Liquidity: EUR 1,487 m undrawn headroom after commercial-paper backup; EUR 930 m new or refinanced bank debt in H1 2026.
  • ESG credentials: FT Climate Leaders 2026 (4th of 34 real estate companies); Cofinimmo's 12 straight EPRA sBPR Gold awards, GRESB 72/100, Sustainalytics "negligible risk".

Weaknesses

  • Tenant concentration: Clariane 12% plus Colisée 7% of rent; Colisée went through a court-supervised recovery plan in 2025–2026.
  • Non-core exposure: offices EUR 874 m (7%) and pubs EUR 468 m (4%) dilute the healthcare pure-play story; M10 is only 57% let.
  • Leverage metrics: net debt/EBITDA 8.3x and debt-to-assets 42.7%, both up from 7.8x and 40.8% at end-2025.
  • Pipeline yield dilution: average initial yield on cost fell from 6.5% to 5.8% with the legacy Cofinimmo Spanish projects.
  • Short debt maturity: weighted average committed debt maturity of 3.3 years; EUR 1,003 m of treasury notes due within 2026.
  • Integration complexity: nine countries, two legacy IT/organisation stacks; litigation inherited from Cofinimmo's former developer partners in Spain and Germany.

Opportunities

  • Synergies: at least EUR 16 m run-rate during 2027 (~EUR 0.17/share on 92.6m shares, derived), versus EUR 5.5 m in 2026.
  • Demographic demand: EU/UK over-80 population projected to grow from >31 m (2025) to >60 m (2060); Spain needs ~237,000 extra beds by 2035.
  • Valuation recovery: six consecutive quarters of positive like-for-like valuations; prime yields decompressed 50–100 bps in 2023–2024 and could re-compress.
  • Non-core monetisation: office and pub disposals (e.g. Egmont bare ownership, 14 pubs in 2026) can fund healthcare growth without equity.
  • Credit-driven bond issuance: an A3/BBB+ profile supports cheaper unsecured debt (possible autumn 2026 bond).
  • Operator consolidation: fragmented markets in Germany, the UK and Spain offer sale-and-leaseback pipelines.

Threats

  • Transfer-tax claims: German RETT ~EUR 45 m and Dutch transfer tax ~EUR 63.4 m if the authorities reject Aedifica's position (H1 2026 risk section).
  • Rate rollover: Cofinimmo-legacy hedges decline toward 71% coverage by 2029; Cofinimmo projected a ~2.3% cost of debt by 2028.
  • Operator stress: wage inflation and staffing shortages; Armonea represents ~7% of rent.
  • Remedy execution: the EUR 300 m Belgian sale must go to a buyer able to become a significant Belgian player, which may limit price tension.
  • Share price below NAV: EUR ~62 versus EPRA NTA EUR 77.82 (~20% discount, derived), limiting accretive equity issuance.
  • Regulatory and political risk: changing reimbursement regimes, French registration duties, Belgian policy emphasis on home care.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
01.05.2025Aedifica proposes exchange offer for Cofinimmo at 1.16Start of the largest Belgian REIT consolidation
09.05.2025Cofinimmo board unanimously rejects terms as undervaluing the companyNegotiating leverage for Cofinimmo
13.05.2025Cofinimmo proposes 1.21; Aedifica AGM heldBid-ask framed
14.05.2025Cofinimmo OGM; Ann Caluwaerts appointed independent directorGovernance refresh
03.06.2025Agreement at 1.185 with balanced 5+5+CEO board; ~EUR 16 m synergies targetedRecommended deal
04.06.2025S&P places Cofinimmo on positive watch; Aedifica BBB placed on CreditWatch positiveCredit upside
Jun 2025Aedifica EGM approves capital increase for offerFunding authority secured
Jul 2025German and Dutch competition approvals; French FDI clearanceRegulatory progress
18.07.2025BCA raises additional questions; timeline at riskFirst setback
Jul 2025Cofinimmo divests Le Ménil (BE) and Hélio Marin (FR)Rotation
30.09.2025Further BCA update; remedy discussionsDelay into 2026
Oct 2025Aedifica proposes ~EUR 300 m Belgian asset saleRemedy above market expectations
05.11.2025S&P reiterates positive watch on CofinimmoCredit stable
Dec 2025Cofinimmo early-refinances EUR 344 m syndicated facility to 2027; new EUR 100 m bilateral line2026 maturities cut to EUR 267 m
21.01.2026BCA conditional clearance with EUR 300 m divestmentDeal unblocked
28.01.2026Cofinimmo sells Prince Royal (Brussels)Rotation
29.01.2026Prospectus and Response Memorandum published; offer opens 30.01Offer launched
13.02.2026Aedifica FY2025: EPRA EPS EUR 5.15 (+4%), DPS EUR 4.00Pre-merger base
20.02.2026Cofinimmo FY2025: EPRA EUR 246 m, EPS EUR 6.45, net result EUR 213 m, DPS EUR 5.20Final full-year standalone results
03.03.202679.57% of Cofinimmo tendered; offer not reopenedControl achieved
10.03.2026Settlement; new board; Cofinimmo board reconstitutedChange of control
13.03.2026S&P upgrades Aedifica to BBB+ / A-2Lower funding cost
21.04.2026Colisée recovery plan approved by Paris Economic Affairs CourtReduces Armonea tail risk
22.04.2026Cofinimmo Q1 2026: EPRA ~EUR 62 m (+8.3% per aggregator), NTA EUR 93.98, D/A 42.1%Last standalone quarter
30.04.2026Merger proposal filed; EGMs convenedPath to delisting
13.05.2026Cofinimmo OGM approves 2025 dividendDividend paid 19.05.2026
19.05.2026Aedifica Q1 2026: EPRA EUR 74.5 m (+19%), EPS EUR 1.32, badwill EUR 314.4 m, NTA EUR 80.34First consolidated quarter
12.06.2026Aedifica EGM approves merger (>99.99%)–
15–23.06.2026FT Europe's Climate Leaders 2026 (4th of 34 real estate companies); TIME 750 Most SustainableESG recognition
16.06.2026Treasury notes programme raised to EUR 1.5 bnLiquidity
30.06.2026Cofinimmo EGM approves merger; last trading day–
01.07.2026Merger effective; Cofinimmo delisted; Jean Hilgers becomes Chair; new ExCo (Bicici, Dumont join)Integration phase
Jul 2026Klein Veldekens campus transferred from Armonea to VulpiaTenant de-risking
20.07.2026S&P reconfirms BBB+ stable–
23.07.2026UK (North Bay) and Spain (Bilbao) acquisitions and forward purchasesGrowth restart
01.09.2026H1 2026: EPRA EPS EUR 2.71 (+5%), guidance EUR 5.35, DPS EUR 4.20Accretion confirmed
10.09.2026EUR 12.5 m Spanish healthcare campus investment (secondary source)Pipeline
12.10.2026Four Irish projects totalling ~EUR 105 m (headline)Pipeline
14.10.2026Jefferies cuts price target from EUR 70 to EUR 67, Hold (secondary source)Sentiment
15.10.2026Moody's first-time A3 issuer rating, stable; covers ~EUR 1.5 bn senior unsecured notes (secondary source)Second IG rating

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Gross rental revenues fell from EUR 358.5 Mn in FY2024 to EUR 354.7 Mn in FY2025.
Cofinimmo SA — Income Statement: Revenue & Gross Profit
Series (EUR Mn)FY2024FY2025
Gross rental revenues358.5354.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.